This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international
study assessing the efficacy and safety of maintenance olaparib compared with placebo in
BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer
(including fallopian tube cancer or primary peritoneal cancer) who are in complete or partial
response following treatment with standard first-line platinum-based chemotherapy.